Archive
536 articles, sorted by publication time.
More than 50 pharmaceutical companies are investing in research and development, showing that HER2-positive breast cancer remains a core battleground in oncology drug development. But pipeline momentum does not equal clinical victory; the real key is whether therapies can extend survival, reduce toxicity, and answer the difficult question of treatment sequencing.
Antiviral drug development must not only prove that a drug can suppress a virus, but also explain how the virus may escape. The FDA’s new guidance spells out more specific requirements for submitting next-generation sequencing data, turning genetic data from a research appendix into evidence that reviewers can rerun and verify.
The approval shifts the treatment goal from lowering lipid numbers toward preventing acute pancreatitis, but the clinical benefit still needs to be understood in the context of dietary control, long-term safety, and individual risk assessment.
Claude Science is not just letting researchers use AI to organize data and run analyses; Anthropic is now hinting that it wants to step directly into candidate drug development, shifting technology companies’ role in life sciences from tool providers to participants that are harder to treat as bystanders.
This progress moves VERAXA’s candidate cancer therapy from a platform narrative toward a test of manufacturability; it is important, but still a long way from proving clinical efficacy.
A major pharmaceutical company is once again bringing AI into its early-stage R&D process. The significance of this collaboration is not how quickly algorithms promise to work, but whether they can generate drug hypotheses strong enough to withstand repeated testing in experiments, clinical studies, and regulatory review.
A positive signal from a late-stage clinical trial has brought renewed investor attention to Genmab and AbbVie’s partnered drug; but before full data are released, its true clinical weight will still have to be measured by the magnitude of efficacy, safety, and replaceability.
The significance of this approval lies not only in the addition of another transplant product, but in pushing allogeneic hematopoietic stem cell transplantation from “replacing the hematopoietic system” toward “reprogramming immune composition”; the real answers will emerge through clinical use, manufacturing consistency, and long-term follow-up.
If a large healthcare market becomes increasingly dependent on overseas medicines and raw materials, the pressure falls not only on the trade account but also further affects drug prices, accessibility, and public health resilience.
Immune checkpoint inhibitors have changed cancer treatment, yet it remains difficult to predict in advance who will benefit. The new BioCOMPASS model calibrates predictions using multiple biomarkers and treatment information. Initial data show improved accuracy, but validation hurdles remain before it can become a clinical decision-making tool.
A new study shifts the focus from directly killing cancer cells to immune cells that have been “co-opted” within the tumor microenvironment; if the metabolic state of macrophages can be reshaped, immunotherapy may be able to work in more patients.
Insilico’s new collaboration with Takeda puts generative AI into a drug development workflow closer to pharmaceutical decision-making; but the undisclosed targets, disease areas, and validation design mean the scientific value of the deal still has to be answered by experimental and clinical data.